Bloomberg Stock Movers
2026-11-03 · Hosted by — · Bloomberg / iHeartMedia
Executive Summary
Pfizer raised its full-year outlook after beating on both the top and bottom line in the third quarter, even as shares dipped slightly (down 0.2% pre-market) on weakness in its pneumococcal vaccine line (part of the Prevnar family), which came in below estimates. The company also made Cecilia Guigan's role as CFO permanent after she had been serving on an interim basis. Apollo Global Management posted in-line results, with assets under management reaching $1.06 trillion and adjusted net income up almost 5% to $1.3 billion, though its roughly $23 billion private equity flagship fund posted a 2.6% quarterly loss; the stock traded roughly flat.
Key Stories & Changes
1. Pfizer Raises Full-Year Outlook on Beat, Vaccine Line Lags
Shares traded down about 0.2% in the pre-market despite the raised guidance
The quarter beat on both revenue and earnings; weakness was concentrated in the Prevnar pneumococcal vaccine family, which came in below estimates
Most other product lines beat estimates; the company continues working to grow demand for newer medicines to offset declining COVID-related product sales
Cecilia Guigan was made permanent CFO after serving in an interim capacity
2. Apollo Global Management Posts Record AUM, Flagship Fund Dips
APO: Apollo Global Management — Roughly flat — AUM hit $1.06 trillion; adjusted net income up ~5% to $1.3 billion, meeting estimates
The firm's roughly $23 billion private equity flagship fund posted a 2.6% quarterly loss
New lending activity was a record for the third quarter, benefiting from the firm's growing involvement in AI-related lending
Fees and margins improved amid growing turbulence in global debt markets
3. Apple's Guidance Seen as "Not Good Enough" Despite Beat
AAPL: Apple — Weighing on sentiment — Holiday revenue guide of 7-10% growth beat estimates, but thinning margins drove a cautious read
iPhone revenue hit nearly $58 billion for the fiscal fourth quarter, the highest ever for that specific period, including an all-time sales record in India
Margins are expected to be thinner going forward as component costs rise, particularly from higher memory costs; Apple has already raised prices to help offset the impact
4. Palantir Drops on Slowing Growth Signals
PLTR: Palantir — -8% — Guidance implies ~15% sequential growth, one of the slowest readings in a while
Remaining performance obligations (contracted revenue not yet delivered) came in more than $1 billion below estimates as of quarter-end
The company added 41 new customers versus a consensus expectation of more than 60
Trends Identified
1. Big Pharma Earnings Show Resilient Core Business Despite Pockets of Weakness
Pfizer's beat-and-raise quarter, despite one weak vaccine franchise, suggests the broader pharmaceutical earnings cycle remains solid even as individual product lines face demand normalization post-COVID.
2. AI-Driven Lending Supporting Alternative Asset Managers
Apollo's record new lending, tied in part to its growing role financing AI-related ventures, shows how the AI buildout is creating knock-on revenue opportunities for private credit providers even as some underlying funds see mark-to-market volatility.
3. The Market Is Penalizing Growth Deceleration, Not Absolute Beats
Both Apple and Palantir beat or guided above consensus on top-line metrics, yet both faced negative market reactions tied specifically to forward-looking deceleration signals — Apple's margin outlook and Palantir's slowing sequential growth and lighter bookings — underscoring how sensitive the market has become to the second derivative of growth. ---
Sentiment Analysis
Overall Market Sentiment: Mixed, Growth-Deceleration Sensitive
The session reflected a market parsing nuance within beats, rewarding absolute strength (Pfizer, Apollo) while punishing forward signs of margin or growth deceleration (Apple, Palantir).
Risk Factors Highlighted
Apple margin compression: Rising component and memory costs are expected to thin margins going forward despite strong holiday revenue guidance.
Palantir bookings shortfall: Remaining performance obligations coming in over $1 billion below estimates signals potential future revenue growth deceleration.
Palantir customer growth miss: Adding 41 new customers against a consensus of over 60 raises questions about sales momentum.
Pfizer vaccine franchise softness: The Prevnar line's miss highlights ongoing normalization risk as COVID-era product demand fades.
Private equity mark-to-market volatility: Apollo's flagship fund's quarterly loss shows private equity valuations remain exposed to volatility despite overall AUM growth.
This episode was covered in today's [The Market Signal — 2026-11-03](https://marketsignal.beehiiv.com/p/the-market-signal-2026-11-03), a cross-source synthesis of multiple podcast reports.